louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00994734: Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion
Official title: Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Termination of Pregnancy
Lead sponsor: Gynuity Health Projects
Sponsor class: OTHER
First posted: 2009-10-14
Enrollment: 615
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The primary aim of this study is to assess the acceptability of home-use mifepristone for termination of pregnancy among women who choose it and their providers. The investigators' secondary aims are to assess rates of follow-up, adherence, efficacy, complications, lost productivity, and to estimate the minimum proportion of women who choose home-use over clinic use of mifepristone.


Eligibility criteria: Inclusion Criteria:

* Reproductive age women seeking abortion services.
* Eligible women will be in general good health and assessed by a clinician to have an intrauterine pregnancy less than 64 days L.M.P on the day mifepristone will be taken.
* Participants must be eligible for medical abortion according to clinician and clinic standards.
* In the United States, women only 18 years and older will be eligible to participate, unless the study site obtains a waiver to include minors.

Primary outcomes:
measure: Proportion of women who select home-use of mifepristone
timeFrame: 1-2 weeks
measure: Satisfaction with Method
timeFrame: 1-2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Feminist Women's Health Center
state: Georgia
city: Bronx
country: United States
facility: Family Health Center, Montefiore Medical Center
state: New York
city: New York
country: United States
facility: Institute for Family Health
state: New York
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
city: Chisinau
country: Moldova, Republic of
facility: Municipal Clinical Hospital
city: Kathmandu
country: Nepal
facility: Kathmandu Medical College
city: Kathmandu
country: Nepal
facility: Nepal Medical College Teaching Hospital
Study officials:
References:
citation: Conkling K, Karki C, Tuladhar H, Bracken H, Winikoff B. A prospective open-label study of home use of mifepristone for medical abortion in Nepal. Int J Gynaecol Obstet. 2015 Mar;128(3):220-3. doi: 10.1016/j.ijgo.2014.09.022. Epub 2014 Nov 27.
Clinical trial NCT00297934: Spinal Manipulative Therapy: Dual-Task Performance
Official title: Influence of Instrument-Applied Spinal Manipulative Therapy on Dual-Task Performance Involving Complex Postural and Cognitive Tasks
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Balance
Keywords: dual-task
postural control
cognitive
Lead sponsor: Logan College of Chiropractic
Sponsor class: OTHER
First posted: 2006-03-01
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purposes of this study is to determined the effects of instrument applied spinal manipulative therapy upon dual-task performance involving complex postural and cognitive task.

Detailed description: This study sought to determine whether a 2-week regimen of spinal manipulative therapy could improve postural control under 2 conditions. Condition one was a complex postural task which consisted of a shoulder width stance on a compliant surface with eyes closed to remove visual input. Condition 2 was as above with the addition of visio-spatial cognitive task (serial 7s subtraction). These tasks were performed on a force-place designed to capture center of pressure data. Data was captured prior to the onset of therapy and then again after 6 treatment sessions (2-week period). Data was also collected 1 week post treatment to note any lasting effects following therapy. This pilot study utilized a repeated measures designed with no control group.

Eligibility criteria: Inclusion Criteria:

* Healthy participants

Exclusion Criteria:

* No injuries
* No surgeries
* No visual, vestibular, or somatosensory disorders capable of affecting balance

Primary outcomes:
measure: Sway velocity using a NeuroCom Balance Master Forceplate
Secondary outcomes:
Other outcomes:
Locations:
city: Chesterfield
country: United States
facility: Logan College of Chiropractic
state: Missouri
Study officials:
affiliation: Logan College of Chiropractic
name: Rodger Tepe, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00229034: Effect of APC and Epo on the Inflammatory Response During Sepsis
Official title: Effect of Activated Protein C and Erythropoietin on the Microvascular Inflammatory Response During Severe Sepsis.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sepsis
Systemic Inflammation
Keywords: Systemic Inflammation
Microvascular Perfusion
Septic Shock
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2005-09-29
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients in the ICU in severe septic shock receiving either APC and/or Epo

Brief summary: An observational study to determine the effect of APC and Epo in reducing the systemic inflammatory response during severe sepsis.

Detailed description: An observational study to determine the effect of APC and Epo in reducing the systemic inflammatory response during severe sepsis. Patients already prescribed either drug will be enrolled. The microcirculation of the sublingual vascular bed will be observed with a microscope to detect the alterations in the inflammatory response.

Eligibility criteria: Inclusion Criteria:

* patients in the ICU in severe septic shock undergoing APC and/or Epo treatment

Exclusion Criteria:

* any severe comorbid conditions

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: Canada
facility: Lawson Health Research Institute
state: Ontario
Study officials:
affiliation: Scientist
name: Amit Badhwar, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Surgeon
name: Neil Parry, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06868134: Efficacy of Exercise Methods in Postmenopausal Women: a Clinical Trial
Official title: The Effectiveness of Different Exercise Application Methods in Postmenopausal Women
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Post Menopausal Women
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2025-03-10
Enrollment: 60
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to evaluate the effectiveness of different exercise methods in improving health outcomes for postmenopausal women. As women go through menopause, they may experience changes such as decreased bone density, muscle weakness, and an increased risk of chronic diseases. Exercise is known to be beneficial in reducing these risks, but the best approach remains unclear.

In this clinical trial, participants will engage in structured exercise programs designed to improve bone health, strength, and overall well-being. The study will compare different types of exercises to determine which method provides the most benefits. By participating in this research, postmenopausal women can contribute to a better understanding of how exercise can enhance health during this stage of life.

This study is safe, and all exercises are guided by professionals. The results will help healthcare providers recommend the most effective exercise strategies for postmenopausal women.


Eligibility criteria: Inclusion Criteria:

* Being between 40-65 years of age Having a Body Mass Index (BMI) below 40 Scoring 68 or above on the System Usability Scale Having no orthopedic problems Completing the informed consent form Being within 5 years after a 12-month amenorrhea history

Exclusion Criteria:

* Presence of visual impairments Presence of musculoskeletal system disorders Presence of cognitive impairments Presence of joint range of motion limitations Presence of severe cardiac problems Participation in another program

Primary outcomes:
measure: Body Composition (Fat Mass, Lean Mass, and BMI) Assessed by Bioelectrical Impedance Analysis (BIA)
timeFrame: Baseline and Week 8
Secondary outcomes:
measure: Menopause Symptom Assessment Scale Score
timeFrame: Baseline and Week 8
measure: Fatigue Severity Scale Score
timeFrame: Baseline and Week 8
measure: Beck Depression Inventory (BDI) Score
timeFrame: Baseline and Week 8
measure: Pittsburgh Sleep Quality Index (PSQI) Score
timeFrame: Baseline and Week 8
measure: Short Form-36 (SF-36) Quality of Life Scale Score
timeFrame: Baseline and Week 8
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medipol University
state: Beykoz
Study officials:
References:
Clinical trial NCT01954134: P53 in Differentiated Thyroid Cancer
Official title: P53 Antibody; Is it an Indicator of Dedifferentiated Thyroid Cancer?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thyroid Neoplasms
Keywords: Tumor Suppressor Protein p53,
Iodine Radioisotopes
Lead sponsor: Cumhuriyet University
Sponsor class: OTHER
First posted: 2013-10-01
Enrollment: 199
Sex: ALL
Minimum age (years): 16
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 171 patients with an age range of 16-80 yrs (mean: 47.7±13.5 yrs) and a total of 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0±9.8 yrs) were included in this study.

Brief summary: In clinical practise patients with negative radioiodine scan with positive tyhroglobulin is considered as radioiodine resistant or in another words in the process of dedifferentiation. The aim of the present study was to search a simple blood test that could lead to early identification of patients with dedifferentiation. In this respect, we investigate whether the serum level of anti-p53 antibody has the diagnostic value in the follow-up of patients with high levels of thyroglobulin (tg) and negative I-131 scan.

Detailed description: In the present study enrolled were 171 patients with mean age of 47.7±13.5 yrs (range; 16-80yrs) and 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0±9.8 yrs). 134 (78.4%) patients were female and 37 (21.6%) patients were male.

Eligibility criteria: Inclusion Criteria:

* Patients who were diagnosed with DTC
* Treated with total and/or near-total thyroidectomy
* Referred for I-131 ablation therapy or low dose I-131 whole body scan (WBS)
* Between December 2010 and January 2013.

Exclusion Criteria:

* Dose 131-I given in another hospital
* Radioiodine treatment more than one year after thyroidectomy.

Primary outcomes:
measure: There was not any risk for patients.
timeFrame: with in the first 8-10 months after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Sivas
country: Turkey
facility: Cumhuriyet University, School of Medicine, Dept. of Nuclear Medicine
Study officials:
affiliation: Cumhuriyet University
name: Zekiye Hasbek, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wu M, Mao C, Chen Q, Cu XW, Zhang WS. Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case-control study of 569 patients and 879 healthy controls. Mol Biol Rep. 2010 Jan;37(1):339-43. doi: 10.1007/s11033-009-9744-7. Epub 2009 Aug 20.
citation: Muller M, Meyer M, Schilling T, Ulsperger E, Lehnert T, Zentgraf H, Stremmel W, Volkmann M, Galle PR. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol. 2006 Oct;29(4):973-80.
citation: Hasbek Z, Turgut B, Erselcan T. p53 antibody: is it an indicator of dedifferentiated thyroid cancer? Ann Nucl Med. 2014 Jan;28(1):42-6. doi: 10.1007/s12149-013-0783-8.
Clinical trial NCT05793034: Predictive Factors for Survival in Aggressive Meningiomas
Official title: Analysis of Predictive Factors for Overall and Progression-free Survival After Neurosurgery for Atypical or Anaplastic Meningioma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Meningioma
Meningioma Atypical
Anaplastic Meningioma
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor class: OTHER
First posted: 2023-03-31
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.


Eligibility criteria: Inclusion Criteria:

1. Patient operated for atypical (grade 2) meningioma; or
2. Patient operated for anaplastic (grade 3) meningioma;
3. Timeframe for surgery, 1999-2019

Exclusion criteria

1) Patient lost at follow-up

Primary outcomes:
measure: Recurrence-free survival (RFS)
timeFrame: 5 years on average
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: 5 years on average
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Fondazione Policlinico Universitario A. Gemelli IRCCS
Study officials:
References:
Clinical trial NCT02682134: Sore Throat Prevention Following Intubation
Official title: Comparison Between Xylocaine Gel as Endotracheal Cuff Lubricant Versus Dexamethasone 8 mg Intravenously or Both for Sore Throat Prevention Following Intubation: Interventional Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Sore Throat
Keywords: Sore Throat
Intubation
Xylocaine
Dexamethasone
Lead sponsor: University of Jordan
Sponsor class: OTHER
First posted: 2016-02-15
Enrollment: 300
Sex: ALL
Minimum age (years): 15
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The aim of this interventional study is to find out the incidence of sore throat among intubated patients in Jordan university hospital and to find out which is preventive and effective method to decrease sore throat;is it xylocaine gel on endotracheal cuff as lubricant versus dexamethasone 8 mg intravenously or both.

Detailed description: Three groups were divided into: first group received xylocaine gel as endotracheal cuff lubricant,second group received dexamethasone 8 mg intravenously and third group received both( xylocaine and dexamethasone).

The investigator compared between the three groups regarding sore throat in intubated patients and followed them up to 48 hours.

Eligibility criteria: Inclusion Criteria:

* ASA 1-3.
* Elective VS Emergency.
* Cuffed endo-tracheal tubes.
* Different types of surgery.

Exclusion Criteria:

* Pregnant ladies.
* ICU patients.
* \<15 years of age
* Laryngeal mask airway

Primary outcomes:
measure: Comparison in preventing sore throat: xylocaine gel versus dexamethasone or both following intubation.
timeFrame: 4 months
Secondary outcomes:
measure: Sore throat SCALE
timeFrame: 4 months
Other outcomes:
Locations:
Study officials:
affiliation: University of Jordan
name: Aboud Aljabari
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05357534: Perception of Blood Sugar Variations During Physical Activity in Healthy Subjects and Type 1 Diabetes Patients
Official title: Perception of Blood Sugar Variations During Physical Activity in Healthy Subjects and Type 1 Diabetes Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Type 1 Diabetes
Keywords: Type 1 Diabetes
blood sugar variations
physical activity
Lead sponsor: Université de Reims Champagne-Ardenne
Sponsor class: OTHER
First posted: 2022-05-03
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Type 1 diabetes is an autoimmune disease with absence of insulin secretion. Blood sugar is a physiological variable that reflets for blood glucose concentration. Blood sugar level fluctuates, especially during physical activity.

Sports activity would increase insulin sensitivity, improve lifestyle and, by extension, promote glycemic balance. However, glycemic balance will be disturbed by physical activity with higher risk of hypoglycemia and hyperglycemia.

Moreover, hypoglycemia and hyperglycemia will impact body functions. Perceptions of blood sugar variations during physical exercise and their influences on sports performance have not been studied, whether in type 1 diabetes patients or healthy subjects.

Detailed description: The aim of the study is to evaluate the perception of blood sugar variations in healthy subjects and type 1 diabetes patients during physical activity

Eligibility criteria: Inclusion Criteria:

* Type 1 diabetics diagnosed more than 3 years ago and controlled (an HbA1c of less than 8%) for "type 1 diabetes" group
* without diabetes for "healkthy" group
* Male
* Aged 18 to 65
* Body Mass Index less than 30 kg/m2
* regular running (at least 30 minutes per week and at least one 10-km run per year for the previous 2 years)
* Agreeing to participate in the study

Exclusion Criteria:

* Physical injury
* beta blockers treatment

Primary outcomes:
measure: blood sugar
timeFrame: Day 0
measure: Feeling lucidity
timeFrame: Day 0
measure: Feeling fatigue
timeFrame: Day 0
measure: feeling hungry
timeFrame: Day 0
measure: average speed per kilometer Sports performance
timeFrame: Day 0
measure: total running time
timeFrame: Day 0
measure: average running speed
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04764734: A Validation Study of the NightOwl Home Sleep Apnea Test
Official title: A Validation Study of the NightOwl Home Sleep Apnea Test
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sleep Apnea
Lead sponsor: Ectosense NV
Sponsor class: INDUSTRY
First posted: 2021-02-21
Enrollment: 100
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single Group will undergo both gold standard polysomnography (PSG) and NightOwl Sleep Apnea Test
Primary purpose: DIAGNOSTIC

Brief summary: The objective of this study is to evaluate the performance of a miniaturized sleep apnea test, called NightOwl. The system consists of a sensor placed on the fingertip and a cloud-based analytics software. The sensor acquires accelerometer and photoplethysmographic data. The software derives actigraphy from the former, and blood oxygen saturation and peripheral arterial tone (PAT), among other features, from the latter. In order to assess NightOwl's performance, the investigators will compare the apnea hypopnea index (AHI) estimate, defined as the number of respiratory events per hour of sleep, derived by the NightOwl system, to the apnea-hypopnea index (AHI) obtained from manual analysis of the polysomnography (PSG), which is the gold standard for sleep apnea diagnosis. This study will be performed in a sleep lab environment.


Eligibility criteria: Inclusion Criteria:

* Subjects with an indication for an in-lab polysomnography

Exclusion Criteria:

* Intellectually disabled people

Primary outcomes:
measure: The Evaluation of the Level of Agreement (Classification Accuracy) Between Patient Categorization
timeFrame: Through study completion, an average of 1 month.
Secondary outcomes:
Other outcomes:
Locations:
city: Coral Springs
country: United States
facility: Coral Springs Laboratory
state: Florida
city: Hollywood
country: United States
facility: United Sleep Diagnostics Hollywood Laboratory
state: Florida
city: Miami Lakes
country: United States
facility: Miami Lakes Laboratory
state: Florida
city: Pembroke Pines
country: United States
facility: United Sleep Diagnostics Pembroke Pines Laboratory
state: Florida
Study officials:
affiliation: SleepMed RX
name: Jagdeep Bijwadia, MD MBA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01815034: Trancutaneous Monitoring to Avoid Hypercapnea During Complex Catheter Ablations
Official title: Transcutaneous Monitoring to Avoid Hypercapnea During Complex Catheter Ablations: a Joint Quality Initiative Pilot From Cardiac Electrophysiology and Anesthesiology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypercapnia
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
First posted: 2013-03-20
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing catheter ablation for artial fibrillation or ventricular tachycardia

Brief summary: Use of trancutaneous CO2 (TC02) monitoring to aide in titration of sedation of midazolam and fentanyl. Trancutaneous readings validated with invasively obtained specimens from existing arterial sheaths required during AF and VT ablations (trans-septal and retrograde aortic respectively)

Detailed description: Cardiac electrophysiology procedures are typically performed under moderate (conscious) sedation in most centers. Advantages over general anesthesia include facilitating arrhythmia induction, avoidance of intubation and ventilator related complications and shorter post-procedure recovery times for most patients. However, the cumulative respiratory depressant effects of fentanyl and midazolam during prolonged procedures can rarely cause hypoventilation resulting in hypercapnea and respiratory failure. Complex catheter ablations for atrial fibrillation and ventricular tachycardia can exceed 3-5 hours in duration requiring large cumulative doses of midazolam and fentanyl. End tidal CO2 monitors, particularly in non-ventilated patients, have limitations and obtaining frequent arterial blood gas samples are often impractical. It remains unknown if contemporary trancutaneous CO2 monitoring (TCO2)can provide a feasible alternative to avoid over-sedation and resultant respiratory complications during complex catheter ablations with sufficient agreement to invasively obtained PCO2 data.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing catheter ablation for atrial fibrillation (AF) or ventricular tachycardia (VT) under moderate sedation.

Exclusion Criteria:

* Procedures scheduled for general anesthesia

Primary outcomes:
measure: Agreement with invasively obtained PCO2 data within 5 mm Hg
timeFrame: up to 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Daniel J Cantillon, MD
role: PRINCIPAL_INVESTIGATOR
References: